Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

rFIX

Phase 3Small molecule

rFIX is one of 19 small molecule programs targeting Hemophilia B. It is currently in Phase 3.

1

Indications

3

Total Trials

0

Active Trials

18

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hemophilia BActive, not recruiting

Hemophilia BPhase 3

Active, not recruiting

Competition

Competitive Landscape

42 competitors in Hemophilia B

#DrugCompanyPhaseTrials

Recombinant Factor IX Coagulation

IB1001

MMedexus Pharma, Inc.

Translarna

PPTC Therapeutics

BENEFIX

Recombinant Factor IX

BBaxalta now part of Shire

Factor Ix

Nonacog Alfa

Rix-FP

Rfixfc

BBioverativ Therapeutics Inc.

RG7916

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hemophilia B3 trials

Study Evaluating of Recombinant Human Factor IX (BeneFIX) and a New Formulation of BeneFIX (rFIX-R) in Moderate to Severe Hemophilia B

Completed· Pfizer logo

Pfizer·Phase 3·NCT00093210

Study of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Participants With Hemophilia B

Completed·BBioverativ Therapeutics Inc.·Phase 3·NCT01027364·123 enrolled

Study Evaluating rFIX; BeneFIX® in Hemophilia B

Completed· Pfizer logo

Pfizer·Phase 3·NCT00093171·23 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for rFIX. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — rFIX compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for rFIX. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Pfizer

Related News